SYMPOSIA

Poster Presentations
[PP-037] Ref. No: 230
A comparison before and after using lamotrigine in long term continued treatment:
the effect of blood levels
Sermin Kesebir 1 , Fisun Akdeniz 2 , Aysun Demir 1 , Mustafa Bilici 1
1 Erenkoy TEHMND, Istanbul, Turkey
2 Ege University, Psychiatry, Izmir, Turkey
E-mail: serminkesebir@hotmail.com
Objective: The purpose of this study is that determine whether or not the efficacy of lamotrigine, which is an anticonvulsant with a
stabilizer quality in neuronal membranes and has inhibitor activity in sodium and calcium channels and presynaptic neurons, is related
to blood levels in bipolar disorder. We compared the period before and after lamotrigine use in bipolar cases and studied if there was any
relationship between lamotrigine blood levels and clinical progress.
Method: Forty cases, diagnosed with bipolar disorder type I according to the DSM-IV, and taking lamotrigine for at least two years
together with any mood stabilizer (lithium, anticonvulsants or atypical antipsychotics), were evaluated consecutively. For evaluation,
being in remission period was set as a criterion for these cases. Patient interviews were carried out with the SCID-I in bipolar cases. Before
or after protective treatment, the SCIP-TURK Mood Disorders Diagnosis and Patient Registration Form were filled in by the patients and
their relatives. Later blood samples were taken from the bipolar cases in order to analyze lamotrigine blood levels.
Results: In the bipolar cases, when comparing before and after long term maintenance of lamotrigine, it was determined that after using
lamotrigine, total episode and depressive episode frequency decreased, episode severity was less (p< 0.001, 0.039, and 0.04, respectively)
and the fast onset and termination ratio decreased (p= 0.027). When evaluated according to these variables, in long term maintenance,
the ratio of good treatment response to lamotrigine among bipolar cases was 77.5%. In cases with good treatment response to
lamotrigine, while lamotrigine doses were found to be similar to the others (135.5±52.7/155.6±69.7 mg/day), lamotrigine blood levels
were found to be higher (3.8±1.9/2.0±1.1 µg /ml) (p= 0.005). No correlation was shown between lamotrigine dose and lamotrigine blood
levels (r= 0.185, p= 0.254).
Conclusion: As a result, lamotrigine is an efficient choice in long term maintenance treatment of bipolar disorder. The relationship of this
efficacy to lamotrigine blood levels must be explored in future studies.
Key words: Lamotrigine, bipolar disorder, blood level
Bulletin of Clinical Psychopharmacology 2011;21(Suppl. 2):S142
[PP-038] Ref. No: 172
ICAM, VCAM and E-selectin levels in first episode schizophrenic patients
Semine Özdoğan Kavzoğlu, Aytül Gürsu Hariri
Erenköy Research and Training Hospital for Neuropsychiatry, Istanbul, Turkey
E-mail: sokavzoglu@hotmail.com
Objective: It is known that mortality rates in schizophrenic patients with cardiovascular diseases are twice as high as other diseases.
Some of the research has revealed that the risks of cardiovascular disease were dependent on adhesion molecules. The main adhesion
molecules are intracellular adhesive molecule (ICAM-1), vascular cell adhesive molecule (VCAM-1) and E-selectin. The aim of this study
was to determine whether or not ICAM-1, V-CAM-1 and E-selectin levels, which are considered as possible biological determinants in the
prognosis and progression of atherosclerosis, change with treatment in schizophrenic patients with respect to controls.
Method: In the Erenköy Research and Training Hospital for Neuropsychiatry, 50 patients who were diagnosed with first episode
schizophrenia according to the DSM-IV-TR diagnostic criteria and had never received antipsychotic treatment and a control group
consisting of 50 healthy volunteers were enrolled the study. At the beginning of the study (n=50) and after the third month (n=39), ICAM,
VCAM, E-selectin, Fasting Blood Glucose, Total Cholesterol, LDL Cholesterol, HDL Cholesterol and Triglyceride levels were checked in the
plasma of each patient and compared with each other. For the control group, the same biochemical parameters were investigated only at
the beginning of the study. In order to assess the termination of the acute episode, the patient group was given the Positive Symptoms
Assessment Scale (SAPS) and Negative Symptoms Assessment Scale (SANS) in the beginning and at the end of the third month.
Results: In the first episode schizophrenic patients, the average age was 30.14±7.50 years. In the patients, the beginning ICAM-1 levels
were lower than the control group (t= 3.41, p=0.001) and increased during treatment (t=-6.73 p